CFTR Modulator Patent, Pharmaceutical Compositions, Treatment Methods
Summary
The USPTO published patent application US20260092047A1 disclosing CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) modulator compounds of Formula (I), their pharmaceutical compositions, methods of treating cystic fibrosis, and processes for making the modulators. The application also covers solid state forms of Compound 1 and salts and solvates thereof. The application was filed on May 13, 2025, with Application No. 19206359.
What changed
The USPTO published a patent application (US20260092047A1) disclosing novel CFTR modulator compounds for treating cystic fibrosis. The application covers compounds of Formula (I), including their pharmaceutically acceptable salts, deuterated derivatives, and metabolites, along with pharmaceutical compositions comprising these compounds and methods of treating cystic fibrosis using the same. The patent also discloses solid state forms of Compound 1 and salts and solvates thereof. The application names 31 inventors and classifies the invention under C07D chemical compound categories and A61P (respiratory system) therapeutic classification.\n\nPatent applicants and pharmaceutical companies developing CFTR modulator therapies should review this publication for potential freedom-to-operate considerations or competitive landscape implications. This publication does not impose compliance deadlines or regulatory requirements on existing market participants. The patent application represents intellectual property activity in the cystic fibrosis therapeutic space and may inform future drug development strategies.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODULATOR OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
Application US20260092047A1 Kind: A1 Apr 02, 2026
Inventors
Alexander Russell Abela, Timothy Alcacio, Corey Anderson, Paul Timothy Angell, Minson Baek, Jeremy J. Clemens, Thomas Cleveland, Lori Ann Ferris, Peter Diederik Jan Grootenhuis, Raymond Stanley Gross, Anton V. Gulevich, Sara Sabina Hadida Ruah, Clara Kuang-Ju Hsia, Robert M. Hughes, Pramod Virupax Joshi, Ping Kang, Ali Keshavarz-Shokri, Haripada Khatuya, Paul John Krenitsky, Jason McCartney, Mark Thomas Miller, Prasuna Paraselli, Fabrice Jean Denis Pierre, Yi Shi, Muna Shrestha, David Andrew Siesel, Kathy Stavropoulos, Andreas P. Termin, Fredrick F. Van Goor, Johnny Uy, Timothy John Young, Jinglan Zhou
Abstract
Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
CPC Classifications
C07D 401/14 A61P 11/00 C07D 231/20 C07D 401/04 C07D 471/14 C07D 498/14 C07B 2200/13
Filing Date
2025-05-13
Application No.
19206359
Named provisions
Related changes
Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.